Introduction
CRS is a common worldwide disease, which leads to an increase in medical
consumption and a decrease in productivity, also brings a huge burden to
the society1,2,3. The effect of CRS on quality of life
is greater than that of coronary heart disease, myocardial infarction,
rheumatism, hypertension and diabetes4.
ESS is an important method for the treatment of CRS.
Studies9,10 have shown that the poor healing state of
the nasal cavity after ESS is primarily characterized by high levels of
mucosal edema, scarring and osteitis and eventually cause repeated
symptoms and even recurrence. This is even more severe in eosinophilic
or Th2 CRS5,11-14. Therefore, accelerating the process
of nasal epithelialization and the growth rate of epithelial cilia is
one of the important measures to improve symptoms and accelerate the
recovery of patients after ESS.
Rh-bFGF is an active polypeptide that widely exists in the body.
Previous studies found that rh-bFGF can promotes regeneration of
tracheal epithelial tissues15,16. However, there is no
research regarding the effect of rh-bFGF on the growth of nasal mucosa
or cilia after sinusitis surgery.
In this study, we applied rh-bFGF to the nasal cavity after ESS to
determine whether it promotes the epithelization of nasal mucosa and the
growth of cilia. We focused on improvement of symptoms, the L-K
endoscopic score and the growth rate of cilia by the intranasal use of
rh-bFGF.